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The efficacy of mammograms was examined in a standard random1Zed,
controlled trial of 160,921 women who were 39-4 1 years okl at the beginning
of the study.4 The women in the intervention grcup were offered mammograms yearly unllf they reached 48 years old, ard the control group received
no mammograms during the same period. No statistical significance was
shown between the groups for reducing mortality. The total reduction of breast
cancer mortality was 0.4 per 1,000 women assigned to the inrerventJon group.
Six models were evaluated to estimate the relative benefits and harms
of mammogram screening strategies, which varied by mterval (annual and
biennial) as well as by starting and stoppmg ages.5 Mortality was reduced
by 8 percent and 7 percent through extending C'19 age of mammograms to
79 years old for annual and biennial screenings, respecovely. There was a
smaller increase in mortality reduction of 3 percent when screernng began at
Introduction
age 40. The 40-49 age group had almost a doubling of false p:>s1twes when
Breast cancer IS the second most common type ot cancer among women 1n
the U.S.' Screening procedures rhat detect breast cancer In its early stages screernng annually versus those receiving b!enmal screenings. OverdiagnoslS was shown 10 rise with age but was lowered with t:Menntal screening.
are an important element of prevertative health care for women. Official
Results found that b1enn1al screening ach1eves81 pen::ent otthe benefits
guidelines and recommendaoons for screening have been developed to
attamed by annual screening. The increases in false posiuves and overdiagassist women and health care providers in opt1m1zing these procedures. As
these guidelines are modified, their changes impact health care at both the nos1S rates, combined with the lower cancer nsk for those 40-49 years old,
did not support screernng in this age group, according to USPSTF. These
population and individual i:atient levels. Recently, the United States Prevenfindings suggest a greater benefit by increasing the starting age to 50 years
tive Service Task Force (USPSTF) has developed new recommendations
old and the stopping age to 74 years old.
regarding when to start mammogram screening for breast cancer as well as
new recommendations regarding cttnical and self breast exams (Table 1).2 Table 1: ACS and USPSTF Screening Guidelines2 women not at increased
These new recommendations not only have sparked debate, but also have risk tor breast cancer
left many women and health care professionals confused.
ACS
USPSTF
The American cancer Society (ACS) has chosen to adhere to their
current recommendatJons ( Iable 1).2 I he d11terence 1n recommendabOns
Breast selfRegularly for women Reoorrurend agams1 teaching BSE
has prompted vaoous reactions from other advocacy and professional orexam(BSE)
starting in their 20s
ganization as well as health care professionals, not to mention increased
Chroca.I breast PericxfcaUy (atout every Insufficient evtdence lorCBE beyond
patient concerns over the nsks and benefits of screening. Adding ro thtS
exam(CBE)
lhree yeais) for worren screening mammograP,Y 1n women
unease are the financial implications due to possible modifications In
n trer 20s and 30s
40 years or older
insurance coverage and costs.
Periodicafly (every
Abstract
Screening procedures that detect breast cancer in its early stages are
an important element ol preventa:ive health care for all women. When
official guidelines and recommendations lor screening are modified,
their changes imi:act health care at both the population and inclividu?I
i:atient levels. Recently, the United States Preventive Serv:ice Task
Force (USPSTF) has developed new recommendations re{larding
when to s1a11 mammogram screening for breast cancer in women of
average risk lorthe development ol breast cancer. This article dtscusses the ratronale behind the u¢ited USPSTF recommenda11ons and
aIsa presents the current Amenca n Caneer Society (ACS) guideltnes.

USPSTF guidelines
The USPSTF is an independent panel of pnmary care physicians that
assesses the net effectiveness of preventative services by reviewmg the
benefits and harmsofservtces. The controversy began when the group
updated its breast-screening mammogram guidelines for the general population Q.e .. women of average risk for the development of breast cancer)
in November 2009.3 Previously, the 2002 recommendations stated that
women 40 years and older should be screened for breast cancer via mammogram every one to two years. The new 2009 guidelines recommend that
women 40 to 49 years old of average risk should not have regular mammograms unless determined on an individual basis with their health care
provider following a discussion on the benefits and harms of the screening.
These guidelines state that regular mammograms should begin when a
woman of average risk IS SO years old and occur biennially up until the age
of 74. The USPSTF claims the net benefit of screenmg women in both the
40-49 age group and the 50-59 age group is small. However, the USPSTF
recognizes increasing age as the greatest risk factor for breast cancer and.
therefore, recommerds beginnmg screening at 50 years old to accommodate tor greater nsk. The USPSTF's recommendations are based on the
results of several c~mcal trials thatexamme the efficacy as well as benefits
and harms ofscreenrng md11terentage groups.2
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year) for women 40
and over
Wemmograrns Yearly starting at age
40 and continuing for
as long as a woman
is 1n good health.

Reoomrrend benrual screerung iramrrograµiy for worren 50-74
Bienrnal screenm9 before 50 should re
indivK1wf and tal<a i:atirnt context into
accounl, ircltxling tre i:atient's valuas
regarding sµrlic berefns and harms

ACS guidelines
Despite the USPSTF's change in recommendaoons, the ACS stands by its
current recommenda tions. In 1997, the ACS hekl a workshop ID assess data
regarding breast cancer screening and re-evaluated the eXJSong ACS gutdel1nes for early deteCIJOn of breast cancer. The ACS detennined that suffic10nt
data suooested potentially positive Implications for yearly mammograms in
women ages 40-49. Therefore, the 1997 revised recommendaoons included
annual mammograms for women beginmng at age 40. 6
The recommendations of the ACS that were published in 1997 were
delerm1ned from eight randomized, controlled tnals of mammogram screen·
ing. Acco1d1ng to U1e ACS, a 111eta-a11alysis of1:1lleighllitudies published lJy
the NaoonaJ lnstJtute of Health m 1997 demonstrated an 18 ~roent mortarny
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redoction within the 40·49 age group. Two studies conducted in Sweden, the
Gothenburg tnal and the Malmo tnal, also revealed a statisncally significant
redoction in mortality among women in the 40-49 age group.' The Gothenburg trial was a randomized, controlled trial that included 51,611 women,
with 21,650 randomized to ~ive mammograms at 18·month intervals. The
39-49 age group showed a 31-44 percent reduction in mortality after a 14·
year follow-up.7 Accordmg to the ACS, the Malmo trial showed a 36 percent
redoction in mortality after 12 yeais of follow-up. 6 A guideline review was
conducted with a prnel of experts from the ACS in 2003 to review literature
published since the gumlines were established. A meta-analysis conducted
in 2002 revealed a 24 percent decmase in mortality of those invited to
screenirrg in each llial, many of which included the 40-49 age group. As a
result, the 2003 guidelines remained unchanged in regards to the startirrg
age and the frequency of annual mammography.8
Patient concerns
One of the greatest concerns for the patient is the availability of mammograms for women under 50. The guidelines do not say that women
under 50 should not receive mammograms; they state that women under
50 should not automaucally receive mammograms without first speaking
with their physician to weigh their ~rsonal risks and benefits. It 1s also
important for women to real12e !hat the new guidelines pertain only to
women without any nsk factois for breast cancer and, therefore, do not
include patJents with any increased nsk for the disease. Another concern
to health care proroeis with the new USPSTF guidelines rs whether the
cost of mammograms was factored into the studies and that recommendations were 00.sed pnmarily on fiscal considerations. However, the USPSTF
denied that finances were considered and indicated that only the nsks and
benefits of receiving mammograms at certain ages from an epidemiological peispective were used to make their new recommendations. 9

False reassurance and pain and/or discomfort during the procedure are
other minor nsks of mammograms. False reassurance IS the concern that
a neganve test result would deter women trom seektrrg medical advice if
a breast abnormality was observed or found with a self-breast exam. Few
women claimed that pam was a deterrent for routine mammograms, and 1f
a lump were found, a Dutch survey of 516 women found 99 percent of the
women would sbll seek medical advice.10
Financial implications
There are financial implications with the newtask force recommendations regardirrg whether or not third-party payers will continue to cover annual mammograms for women under 50 yeais old. Currently, the u_s. government will
continue to recommend annual mammograms and cover the JXiyment of any
mammogram that is recommended by a health care provider. 12 Of yet, many
private third-party payeis have not charrged their polK:ies and have indicated
that they will continue to evaluate the recommendations before making any
changes to their coverage on mammograms. While many pnvate third-party
payers look to the USPSTF when making their coverage plans, recommendal!Ons of other associations, such as the ACS and the Amertan College of
ObsteUlCS and Gynecology (ACOG), also are considered.
Discussion
The differences 1n the USPSTF and ACS recommendatlOns show that
further research needs to be conducted regarding mammogram screenmg in women age 40-50. Although harms of screening may be more
common with younger age groups, health care professionals should
consider the benefits of beginning screening at an earlier age and
undeistand that mammograms have been pnmanly responsible for a
number of breast cancers being identified and treated earlier. It is always
important for women to discuss these concerns and controversies with
their primary health care provider before making any decisions regarding
mammograms on their own. Although the media intensified the focus on
the changes of the new recommendations, the dec1Sion about when to
obtain a mammogram should be based on individual risk factors.

Benefits and harms of screening
The benefits and nsks of breast cancer screening are atthe forefront of
the debate. Benefits of mammograms include mortality and morbicfny
reduction as wen as µ:ibent reassurance.'
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